Select Page
The EU's IP strategy: Enabler or barrier?
EPHA #A2MDialogues

27 October 2020



Our second dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe. 

How do we ensure that IP incentives compensate and reward innovation but do not distort competition?

What lessons have we learned on IP in the response to COVID19?


Patent-driven innovation may work for profit-driven drug development but it reflects a R&I agenda which favours profit prospects, distortion of competition and market dominance. Additionally, it leads to excessive, unaffordable prices due to monopoly and can stifle meaningful innovation

As the EU prepares to present its IP strategy as well as the scenarios for a review of the legislation on orphan and paediatric medicines, join our experts and key stakeholders who will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition

#A2M Dialogues


Alfonso Calles-Sanchez 

Policy Officer, DG Internal Market, Industry, Entrepreneurship and SMEs (DG Growth) 

European Commission

Dimitri Eynikel

EU Policy & Advocacy Advisor 

Médecins Sans Frontières Access Campaign

Sergio Napolitano

General Counsel & External Relations Director

Medicines for Europe


Thyra de Jongh

Principal Consultant

Technopolis Group

Moderated by

Yannis Natsis,

Policy Manager, Universal Access to Affordable Medicines

European Public Health Alliance

Join our panelists to discuss 

How should the EU orphans and paediatrics legislation be changed?

Is the system rigged to the detriment of generics and biosimilars?

What would a reform of the EU SPC Regulation look like?

Which alternative business models should be pursued in the fields of AMR and vaccine development?

Register for EPHA’s other A2M Dialogues below

Unleashing meaningful innovation through regulatory reform

19 October 2020


Pharma & COVID19: Winners, losers, prospects

19 November 2020


The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines

25 November 2020


Follow on social media




Yannis Natsis

Policy Manager, Universal Access and Affordable Medicines, EPHA